Effects of Conventional and Aggressive Statin Treatment on Markers of Endothelial Function and Inflammation

Clinical Cardiology

Volumn 27, Issue 4, 2004, Pages 199-203

  Hognestad, Aina ^a   Aukrust, Pål ^a   Wergeland, Ragnhild ^a   Stokke, Oddvar ^a   Gullestad, Lars ^c   Semb, Anne Grete ^b   Holm, Torbjørn ^a   Andreassen, Arne K ^a   Kjekshus, John K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NONE

Author keywords

Endothelial markers; Inflammation; Statin treatment

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH SENSITIVE C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PADGEM PROTEIN; SIMVASTATIN; SOLUBLE ADHESION MOLECULE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; DOSE RESPONSE; DOWN REGULATION; DRUG CONTRAINDICATION; DRUG MECHANISM; ENDOTHELIUM; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; PLASMA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 1842583832     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960270405     Document Type: Article

References (35)

1. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126
2. Ridker PM: Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. Curr Cardiol Rep 2000;2:269-273
3. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082
4. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82
5. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357
7. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131
8. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338
9. Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenseter MS: Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med 2001;110: 536-542
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-428
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
12. Rosenson RS: Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999:1:225-232
13. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-431
14. Delanty N, Vaughan CJ: Vascular effects of statins in stroke. Stroke 1997; 28:2315-2320
15. Azar RR, Waters DD: PRINCE's prospects: Statins, inflammation, and coronary risk. Am Heart J 2001;141:881-883
16. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002;251:338-347
17. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme, a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935
18. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Domer GT: Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47-51
19. Ridker PM: High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818
20. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011
21. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999;190: 1733-1740
22. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE: C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999;100:96-102
23. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95: 97-103
24. Ma J, Hennekens CH, Ridker PM, Stampfer MJ: A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999;33:1347-1352
25. Resch KL, Ernst E, Matrai A, Paulsen HF: Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992;117:371-375
26. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641
27. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N: Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood theology in type II hyperlipoproteinemia. Atherosclerosis 1996:122:225-233
28. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A: Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241-243
29. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA: Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:569-570
30. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J: Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:1527-1531
31. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D: Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79:1475-1481
32. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest 2001;108:391-397
33. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-I and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719
34. John R, Rajasinghe HA, Itescu S, Suratwalla S, Lietz K, Weinberg AD, Kocher A, Mancini DM, Drusin RE, Oz MC, Smith CR, Rose EA, Edwards NM: Factors affecting long-term survival (> 10 years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol 2001;37:189-194
35. Laufs U, Endres M, Liao JK: Regulation of endothelial NO production by Rho GTPase. Med Klin 1999;94:211-218